<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477616</url>
  </required_header>
  <id_info>
    <org_study_id>NBC Che001</org_study_id>
    <nct_id>NCT04477616</nct_id>
  </id_info>
  <brief_title>Injection Time Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy</brief_title>
  <official_title>Injection Time Trial of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in Preventing Bone Marrow Suppression and/or Febrile Neutropenia (FN) During Breast Cancer Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try another injection time of PEG-rhG-CSF, which is supposed
      to better prevent bone marrow suppression and/or FN in breast cancer patients who receive
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the occurrent rate of grade III/IV neutropenia during the first chemotherapy cycle</measure>
    <time_frame>start from first cycle of chemotherapy,an average of 3 weeks</time_frame>
    <description>grade III or IV neutropenia (ANC &lt; 1x 10^9/L or 0.5 x 10^9/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the occurrent rate of FN during the first chemotherapy cycle</measure>
    <time_frame>start from first cycle of chemotherapy,an average of 3 weeks</time_frame>
    <description>the occurrent rate of FN（FN：Body temperature ≥38.3°C or ≥38.0°C continued for 1 h, with neutrophil count &lt;500/mcl or neutrophil count &lt;1000/mcl, but expected to drop to &lt;500/ mcl after 48 hours .）</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Experimental/PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 6 (chemotherapy day was record as day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: Comparator/PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 (chemotherapy day was record as day 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 6 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curve of patients at different time periods</description>
    <arm_group_label>Comparator: Comparator/PEG-rhG-CSF</arm_group_label>
    <arm_group_label>Experimental: Experimental/PEG-rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          1. Female breast cancer aged 18-70 years old, the expected survival period is greater
             than 12 months.

          2. No previous radiotherapy and chemotherapy.

          3. No history of serious systemic disease.

          4. KPS≥70.

          5. White blood cell count&gt; 3.5 × 10 ^ 9 / L, neutrophil count&gt; 1.8 × 10 ^ 9 / L, platelet
             count&gt; 100 × 10 ^ 9 / L, hemoglobin&gt; 9 g / dl.

          6. ALT and AST &lt;1.5 times the upper limit of normal value, alkaline phosphatase &lt;2.5
             times the upper limit of normal value, and total bilirubin &lt;1.5 times the upper limit
             of normal value.

          7. Serum muscle plasma &lt;1.5 times the upper limit of normal value.

          8. No abnormal blood coagulation.

          9. Women of childbearing age had a negative serum or urine pregnancy test before the
             start of treatment and agreed to contraception during treatment.

         10. Cardiac function: two-dimensional echocardiography examination LVEF ≥ 55%.

         11. Sign informed consent.

        Exclusion critia:

          1. Received systemic or local treatment for tumors, including chemotherapy, radiotherapy
             and endocrine therapy.

          2. A history of malignant tumors within 5 years (except curable skin basal cell carcinoma
             and cervical carcinoma in situ).

          3. The patient has been enrolled in other clinical trials or used other study drugs 30
             days before enrollment in this study.

          4. Accompanied by uncontrolled lung disease, severe infection, active gastrointestinal
             ulcer need treatment, coagulopathy, severe uncontrolled diabetes, connective tissue
             disease or bone marrow function suppression and other diseases, can not tolerate
             chemotherapy related treatments.

          5. Two-dimensional echocardiography detection LVEF &lt;55%.

          6. Severe cardiovascular and cerebrovascular diseases within the first 6 months of
             randomization (eg unstable angina, chronic heart failure, uncontrollable hypertension&gt;
             150/90 mmHg, myocardial infarction or cerebrovascular accident).

          7. NCI peripheral neurotoxicity grade ≥2.

          8. Those taking glucocorticoids.

          9. Known hypersensitivity to anthracyclines, cyclophosphamide, taxanes, trastuzumab or
             pertuzumab.

         10. Refuse contraception during treatment and within 8 weeks after completion of treatment
             for women of childbearing age.

         11. Pregnant and lactating women.

         12. After joining the test, a pregnancy test (+) before using the drug.

         13. There are mental illness, cognitive impairment, unable to understand the test plan and
             side effects, unable to complete the test plan and follow-up workers (systematic
             evaluation is required before the trial is enrolled).

         14. No personal freedom and independent civil capacity.

         15. The investigator determined that the patient could not obtain long-term follow-up data
             (due to unavailability or serious concomitant diseases).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoming Zha, MD</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jue Wang, MD</last_name>
    <phone>00862568308172</phone>
    <email>wangjue200011@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui Chen, MD</last_name>
    <phone>00862568308172</phone>
    <email>15951756315@163.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Jue Wang</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>PEG-rhG-CSF</keyword>
  <keyword>Bone marrow suppression</keyword>
  <keyword>Febrile neutropenia</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

